Nymox Pharmaceutical Corporation Share Price Nasdaq
Equities
CA67076P1027
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2021 | - | Sales 2022 | - | Capitalization | 29.51M 2.28B |
---|---|---|---|---|---|
Net income 2021 | -12M -926M | Net income 2022 | -6M -463M | EV / Sales 2021 | - |
Net cash position 2021 | 439K 33.87M | Net cash position 2022 | 1.23M 94.9M | EV / Sales 2022 | - |
P/E ratio 2021 |
-8.5
x | P/E ratio 2022 |
-4.39
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 57.95% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Patrick Doody
BRD | Director/Board Member | - | 11/07/23 |
Director/Board Member | - | 20/03/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 07/06/06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Director/Board Member | 88 | 30/06/15 |
1st Jan change | Capi. | |
---|---|---|
+22.15% | 46.56B | |
+45.32% | 41.67B | |
-2.37% | 41.16B | |
+33.84% | 32.4B | |
-6.35% | 28.1B | |
+20.42% | 28.18B | |
+48.83% | 14.52B | |
+45.00% | 13.74B | |
+0.06% | 12.17B |